Category: Therapeutic Area
Global Therapeutic Area
-
Ophthalmic Pharmaceutical Drugs
... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More
-
Infectious Disease Diagnostics
... at a CAGR of 5.5% over the analysis period 2024-2030. Diagnostic Assays & Reagents, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$25.8 Billion by the ... Read More
-
Orthopedic Surgical Robots
... at a CAGR of 40.2% over the analysis period 2024-2030. Knee Surgery End-Use, one of the segments analyzed in the report, is expected to record a 37.6% CAGR and reach US$6.6 Billion by the end ... Read More
-
Orthopedic Trauma Devices
... at a CAGR of 4.8% over the analysis period 2024-2030. Internal Fixator, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$11.8 Billion by the end of ... Read More
-
Artificial Limbs
... CAGR of 4.6% over the analysis period 2024-2030. Upper Extremity Prosthetics, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$925.8 Million by the end of the ... Read More
-
Endometrial Ablation Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$628.5 Million by the end of ... Read More
-
Vitreous Tamponades
... CAGR of 3.0% over the analysis period 2024-2030. Gaseous Tamponades, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$50.9 Million by the end of the analysis ... Read More
-
Neurology Devices
... CAGR of 5.9% over the analysis period 2024-2030. Cerebrospinal Fluid Management, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$7.1 Billion by the end of the ... Read More
-
Ophthalmic Ultrasound Systems
... at a CAGR of 3.9% over the analysis period 2024-2030. Portable Systems, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Rheumatoid Arthritis Therapeutics
... at a CAGR of 4.1% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
Intrauterine Devices
... CAGR of 3.8% over the analysis period 2024-2030. Hormonal Progestogen-Releasing IUD, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$3.4 Billion by the end of the ... Read More
-
Thoracolumbosacral Orthosis (TLSO)
... at a CAGR of 4.7% over the analysis period 2024-2030. The U.S. Market is Estimated at US$584.5 Million While China is Forecast to Grow at 7.2% CAGR The Thoracolumbosacral Orthosis (TLSO) market in the U.S. ... Read More
-
Artificial Joints
... CAGR of 4.4% over the analysis period 2024-2030. Cemented Joints, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$21.2 Billion by the end of the analysis ... Read More
-
Cancer Diagnostics
... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More
-
Anticoagulants
... 9.2% over the analysis period 2024-2030. NOACs, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$33.4 Billion by the end of the analysis period. Growth in ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical Drugs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis ... Read More
-
Cervical Pillows
... CAGR of 5.4% over the analysis period 2024-2030. Standard Pillows, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.8 Billion by the end of the analysis ... Read More
-
Sexual Enhancers
... CAGR of 7.7% over the analysis period 2024-2030. Male Sexual Enhancers, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$354.9 Million by the end of the ... Read More
-
Antidepressants
... 2.5% over the analysis period 2024-2030. Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end of the analysis period. ... Read More
-
Invisible Orthodontics
... CAGR of 9.2% over the analysis period 2024-2030. Clear Aligners, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$5.5 Billion by the end of the analysis ... Read More
-
In-Vitro Fertilization
... CAGR of 8.0% over the analysis period 2024-2030. In-Vitro Fertilization Equipment, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$684.2 Million by the end of the ... Read More
-
Sperm Banks
... CAGR of 5.3% over the analysis period 2024-2030. Sperm Storage Service, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.2 Billion by the end of the ... Read More
-
Statins
... 1.8% over the analysis period 2024-2030. Synthetic Statins, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by ... Read More
-
Prescription Drugs
... CAGR of 5.7% over the analysis period 2024-2030. Generic Drugsone of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$498.0 Billion by the end of the analysis period. ... Read More
Research Assistance
